IBD genetic risk profile in healthy first-degree relatives of Crohn's disease patients by Kevans, David et al.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved.  
For permissions, please email: journals.permissions@oup.com
209
Journal of Crohn's and Colitis, 2016, 209–215
doi:10.1093/ecco-jcc/jjv197
Advance Access publication October 28, 2015
Original Article
Original Article
IBD Genetic Risk Profile in Healthy First-Degree 
Relatives of Crohn’s Disease Patients
David Kevans,a,b Mark S. Silverberg,a,b Krzysztof Borowski,a 
Anne Griffiths,c Wei Xu,d Venus Onay,a Andrew D. Paterson,e Jo Knightf,g,h 
Ken Croitoru;a,b on behalf of the GEM Project
aZane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada bDivision of 
Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada cDivision of 
Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, The Hospital for Sick Children, Toronto, 
ON, Canada dDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada eThe Hospital for 
Sick Children Research Institute, The Hospital for Sick Children, Toronto, ON, Canada fCampbell Family Mental 
Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada gInstitute of Medical 
Science, University of Toronto, Toronto, ON, Canada hDepartment of Psychiatry, University of Toronto, Toronto, 
ON, Canada.
Corresponding author: Dr Kenneth Croitoru, MDCM, Zane Cohen Centre for Digestive Diseases, Division of Gastroenterol-
ogy, Mount Sinai Hospital, 600 University Ave. Room 437, Toronto M5G 1X5, ON, Canada. Tel: 416-586-4800 ext. 7454; fax: 
416-586-4747; email: KCroitoru@mtsinai.on.ca
Abstract
Background: Family history provides important information on risk of developing inflammatory 
bowel disease [IBD], and genetic profiling of first-degree relatives [FDR] of Crohn’s disease [CD]- 
affected individuals might provide additional information. We aimed to delineate the genetic 
contribution to the increased IBD susceptibility observed in FDR.
Methods: N = 976 Caucasian, healthy, non-related FDR; n = 4997 independent CD; and n = 5000 
healthy controls [HC]; were studied. Genotyping for 158 IBD-associated single nucleotide 
polymorphisms [SNPs] was performed using the Illumina Immunochip. Risk allele frequency 
[RAF] differences between FDR and HC cohorts were correlated with those between CD and HC 
cohorts. CD and IBD genetic risk scores [GRS] were calculated and compared between HC, FDR, 
and CD cohorts.
Results: IBD-associated SNP RAF differences in FDR and HC cohorts were strongly correlated 
with those in CD and HC cohorts, correlation coefficient 0.63 (95% confidence interval [CI] 0.53 - 
0.72), p = 9.90 x 10–19. There was a significant increase in CD-GRS [mean] comparing HC, FDR, and 
CD cohorts: 0.0244, 0.0250, and 0.0257 respectively [p < 1.00 x 10–7 for each comparison]. There 
was no significant difference in the IBD-GRS between HC and FDR cohorts [p = 0.81]; however, 
IBD-GRS was significantly higher in CD compared with FDR and HC cohorts [p < 1.00 x 10-10 for 
each comparison].
Conclusion: FDR of CD-affected individuals are enriched with IBD risk alleles compared with HC. 
Cumulative CD-specific genetic risk is increased in FDR compared with HC. Prospective studies are 
required to determine if genotyping would facilitate better risk stratification of FDR.
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Inflammatory bowel diseases are a group of heterogeneous disorders 
that result in chronic intestinal inflammation affecting the digestive 
tract. The major forms of these disorders, ulcerative colitis [UC] 
and Crohn’s disease [CD], manifest both distinct and overlapping 
clinical and pathological characteristics. In North America, inci-
dence rates range from 2.2 to 14.3 per 100 000 person-years for 
UC and 3.1 to 14.6 per 100 000 person-years for CD. As many as 
200 000 Canadians,1 1.4 million persons in the USA and 2.2 million 
Europeans suffer from these diseases.2 The aetiology of inflamma-
tory bowel disease [IBD] has yet to be fully elucidated; however, it 
is currently thought to arise as a result of a dysregulated immune 
response in genetically susceptible individuals to environmental trig-
gers such as a dysbiotic host microbiota.
Epidemiological studies have provided compelling evidence that 
genetic factors contribute to the pathogenesis of IBD. First-degree 
relatives [FDR] of patients with IBD have approximately a 3 to 
20-fold greater likelihood of developing the disease than the gen-
eral population.3,4,5 The siblings of patients with CD have an esti-
mated relative risk of developing CD up to 35 times the background 
population risk.4 Offspring where both parents have CD have even 
greater risk with approximately 36% likely to develop the disease.6 
Ashkenazi Jews also have an increased risk of IBD.7,8 However, most 
significantly, twin studies have indicated that heritability is high in 
CD with concordance rates in monozygotic of 27–50% compared 
with 2–4% in dyzygotic twins.9,10,11 Consistent with epidemiological 
predictions, over 70 IBD-associated genetic associations were iden-
tified in candidate gene,12 linkage,13 and genome-wide association 
studies [GWAS].14,15,16,17,18,19,20,21 More recent meta-analysis of CD 
and UC genome-wide association scans, followed by validation of 
significant findings using Immunochip genotyping [Illumina Inc.]22 
of independent case-control cohorts identified further associations, 
increasing the number of IBD-associated risk loci to 201.23,24
Family history alone provides important information regarding 
an individual’s risk of developing IBD, and genetic profiling of FDR 
of CD-affected individuals might provide additional information 
on disease susceptibility risk. Since the genetic risk of IBD has been 
defined through GWAS in large case-control studies, the representa-
tion of these IBD risk alleles in FDR needs to be defined. Genetic risk 
in FDR of CD-affected individuals is assumed to be increased based 
on previous epidemiological data,3,4,5 but it is not known to what 
degree this is the case. In this study we aimed to define the genetic 
contribution to the increased IBD susceptibility observed in FDRs 
of CD-affected individuals by comparing the carriage of 163 known 
IBD-associated risk loci,23 between FDR, CD-affected individuals, 
and a healthy control cohort [HC]. In addition we examined differ-
ences in cumulative genetic risk between HC, FDR, and CD cohorts 
by comparing IBD and CD genetic risk scores between these cohorts.
2. Material and Methods
2.1. Study population
FDR were enrolled by identifying probands with CD and recruiting 
their healthy FDR siblings and offspring from sites around Canada 
and the USA as part of the Genetics, Environmental, Microbial 
[GEM] Project [www.gemproject.ca]. Only FDR between 6 and 
35  years of age were enrolled. The diagnosis of CD in probands 
was established by review of history and clinical information avail-
able to the recruiting physicians. FDR were defined as full sibling 
or offspring as declared by the proband and subject. For FDR, the 
criteria of a ‘healthy’ or ‘disease-free’ state was defined by the GEM 
Project clinical sub-committee and includes lack of any history of 
gastrointestinal diseases. At study entry, each subject completed a 
standard questionnaire to ensure the absence of symptoms related 
to gastrointestinal illness. Eligibility included a lack of gastrointesti-
nal symptoms considered significant, such as: unintentional weight 
loss in the past 3 months greater than 15% of baseline; recurring 
abdominal pain more than once weekly for greater than 3 months 
in the past year; diarrhoea more than three times per day of greater 
than 3 months’ duration in the past year; and blood in stools. Other 
exclusion criteria include diagnosis with diabetes or pregnancy at 
time of enrolment. As of January 2014, there were 1037 FDR with 
available genotyping data. From this cohort, only Caucasian FDR 
who were the first recruited individual in a family were included, 
resulting in a final study cohort of 978 [72% siblings, 28% off-
spring]. The baseline demographics of the FDR cohort are detailed in 
Supplementary Table 1, available as Supplementary data at ECCO-
JCC online.
A healthy control [HC] cohort and Crohn’s disease [CD] cohort 
from the International IBD Genetics Consortium [IIBDGC] reposi-
tory were also utilised in analyses. Subjects in the CD cohort were 
not related to individuals in the FDR cohort. From the CD cohort 
a random sample of 5000 CD Caucasian subjects were selected 
from the 14 763 CD-affected individuals, with Immunochip geno-
typing, examined by Jostins et  al.23 Similarly for the HC cohort, 
5000 Caucasian HC were randomly selected from a total of 15 977 
healthy controls, with Immunochip genotyping, examined by Jostins 
et al.23 Data on age at enrolment / diagnosis and proportion of sub-
jects of Jewish ethnicity in the HC and CD cohorts were not avail-
able [Supplementary Table 1].
2.2. Genotyping—technique and quality control
For FDR, one purple-top [EDTA] vacutainer [BD Inc., NJ, USA] con-
taining whole blood was collected from each subject and genomic 
DNA extracted using the Gentra Puregene Blood Kit [Quiagen, CA, 
USA]. Each DNA sample was quantified by Nanodrop at 20 ng/µl 
and aliquoted into 96-well reaction plates. Single nucleotide poly-
morphism [SNP] genotyping was performed using the ImmunoChip 
[Illumina Inc., San Diego, CA, USA]. SNP quality control was per-
formed using PLINK:25 SNPs with missingness >5 % and Hardy-
Weinberg equilibrium [HWE] outliers [p ≤ 1 x 10–6] were removed. 
All pairs of subjects were tested for an identity-by-descent value 
greater than 0.1875 to avoid relatedness in the dataset. Two subjects 
from FDR and three subjects from the CD cohort were removed due 
to an identity-by-descent value greater than 0.1875. The remaining 
samples were used to analyse population structure in the cohorts. 
Population structure was assessed using HapMap Caucasians and 
multiple dimension scaling [MDS]. MDS was performed on 10 725 
SNPs with r2 < 0.2 with a cutoff of 8 standard deviations [SD] for 
outliers. No outliers were identified and therefore no samples were 
removed based on population structure analysis. [Supplementary 
Figure  1, available as Supplementary data at ECCO-JCC online] 
Following quality control as described above, 4997 of the CD 
cohort, 976 of the FDR cohort, and 5000 of the HC cohort were 
available for analysis. In this report we focused analyses on the 163 
recently reported IBD-associated Immunochip SNPs of which 158 
passed quality control assessments [Supplementary Table  2, avail-
able as Supplementary data at ECCO-JCC online ].23 As an extra 
validation step, the insertion C polymorphism [rs2066847] in nucle-
otide-binding oligomerisation domain-containing protein 2 [NOD2] 
was genotyped using the TaqMan 5’Nuclease Allelic Discrimination 
assay [Applied Biosystems, CA, USA]. TaqMan genotyping of 
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rs2066847 was in complete agreement with Immunochip genotyp-
ing of rs5743293; therefore these were considered to be identical 
variants. The variant on the Immunochip with id rs2066847 did 
not agree with TaqMan genotyping of this variant and was thus 
discarded.13,23
2.3. Comparisons of IBD-associated SNP allele 
frequency in FDR, CD, and HC cohorts
PLINK was applied to provide summary statistics for each of the 
SNPs, including allele frequency, genotype distribution, and HWE 
test for each cohort. Further analyses were performed using SAS 
v.9.2 [SAS Institute, NC, USA]. Logistic regression models were 
applied for each of the SNPs to compare FDR, HC, and CD cohorts 
using an additive genetic model. Odds ratios [OR] were estimated 
for each comparison with accompanying p-values. In this analy-
sis, correction for multiple testing was performed using Bonferroni 
correction [based on the number of SNPs included in the analy-
sis] with a threshold for significance of p = 3.2 x 10–4. For the 158 
IBD-associated SNPs, the difference in risk allele frequencies [RAF] 
between HC and CD cohorts, and HC and FDR cohorts, was cal-
culated. The correlation between these RAF differences was then 
assessed using Pearson’s correlation with an accompanying p-value.
2.4. Genetic risk scores—calculation and 
comparison across study cohorts
A weighted GRS was calculated, which utilised the 158 available 
IBD risk loci on the Illumina Immunochip. For each risk allele, the 
genetic burden conferred was calculated, using PLINK, by multiply-
ing the log transformation odds ratio [OR] of its association with dis-
ease by the allele dose [wild type, heterozygote or homozygote]. ORs 
were taken from the report by Jostins et al.23 Wild type, heterozygote 
and homozygote genotype for a given allele were assigned weights 
of 0, 1 and 2 respectively. The cumulative genetic risk score [GRS] 
was then calculated by adding together the contribution of each of 
the risk loci [log OR x allele dose] and then dividing by the number 
of non-missing SNPs. Two risk scores were calculated: an IBD-GRS 
which summed the contribution of 158 IBD risk loci; and a CD-GRS 
which summed the contribution of specifically CD-associated risk 
loci [n  =  30]. The mean IBD-GRS and CD-GRS were compared 
between HC, FDR, and CD cohorts using t tests with uncorrected 
p-values reported in these analyses and a threshold for significance 
set at p  <  0.05. Comparisons of IBD-GRS and CD-GRS between 
various subgroups of the FDR cohort were also made. Although CD 
probands related to recruited FDR were not included in the study, 
baseline demographic data on these individuals were available. 
Using these data, the correlation of FDR genetic risk scores with the 
age at diagnosis of their corresponding CD proband was performed 
[Pearson correlation coefficient with accompanying p-value]. The 
mean IBD-GRS and CD-GRS were also compared between: sibling 
and offspring FDR; and FDR whose age at enrolment was less than 
17 years compared with those of 17 years or greater; and t tests with 
uncorrected p-values were reported for these comparisons [threshold 
for significance set at p < 0.05] (SAS v.9.2 [SAS Institute, NC, USA]).
2.5. IBD and CD genetic risk categories in FDR and 
HC cohorts
For IBD genetic risk, FDR and HC cohorts were grouped into four 
genetic risk categories [category 1, lowest genetic risk to category 4, 
highest genetic risk]. For these IBD genetic risk category assignments, 
the CD cohort was considered a reference cohort, and IBD-GRS ref-
erence ranges were developed by dividing this cohort in quartiles 
based on IBD-GRS values. The reference range for each IBD-GRS 
quartile derived from the CD cohort was then applied to HC and 
FDR cohorts, allowing subjects in these cohorts to be assigned to 
one of the four IBD genetic risk categories. A similar approach was 
taken to categorise subjects in the FDR and HC cohorts into four 
categories of CD genetic risk categories [category 1, lowest genetic 
risk to category 4, highest genetic risk]; however, in this instance, 
reference ranges for each genetic risk category were derived by divid-
ing the CD cohort into quartiles based on their CD-GRS values. For 
IBD and CD genetic risk categories, the proportion of subjects in HC 
and FDR cohorts in each of these categories was compared using the 
chi-square test for trend with p-values < 0.05 considered significant 
(SAS v.9.2 [SAS Institute, NC, USA]).
2.6. Ethical considerations
The study was reviewed and approved by the research ethics boards 
at all recruitment sites, and all subjects provided written informed 
consent for inclusion in the study. 
3. Results
3.1. Comparison of IBD-associated allele 
frequencies in HC, FDRs, and CD
Comparing FDR and HC cohorts, the RAF of two of the 158 IBD-
associated SNPs assessed differed significantly in RAF: rs2188962 
[IBD5 locus], OR 1.21, p  =  9.2 x 10–5 and rs3764147 9Laccase 
Domain Containing 1 [LACC1]], OR 1.23, p  =  1.9 x 10–4). 
Comparing FDR and CD cohorts, one of the 158 IBD-associated 
SNPs assessed differed significantly in RAF: rs6863411 (Sprouty 
Homolog 4 [SPRY4], Nedd4 family interacting protein 1 [NDFIP1]), 
OR 0.77, p = 2.3 x 10–7). Aside from those described above, none 
of the other SNPs assessed differed in RAF, comparing FDR with 
HC or CD cohorts, at a level which reached the pre-defined p-value 
threshold for significance [p  =  3.2 x 10–4] [Supplementary Tables 
3 and 4, available as Supplementary data at ECCO-JCC online]. 
For the 158 IBD-associated SNPs evaluated, the differences in RAF 
between FDR and HC cohorts were strongly correlated with the dif-
ferences in RAF between CD and HC cohorts; correlation coefficient 
0.63 (95% confidence interval [CI] 0.53 - 0.72), p = 9.90 x 10–19; 
and RAF differences were generally in the same direction but of a 
lower magnitude[Figure 1]. In contrast, where the same comparison 
was made using 140 randomly selected non-IBD associated SNPs, 
the differences in minor allele frequency [MAF] between FDR and 
HC cohorts versus CD and HC cohorts were less strongly corre-
lated (correlation coefficient 0.23 [95% CI 0.07 - 0.38], p = 0.003) 
[Supplementary Figure 2, available as Supplementary data at ECCO-
JCC online].
3.2. Genetic risk score comparisons in HC, FDR, and 
CD cohorts
CD-associated genetic risk was significantly greater in the FDR com-
pared with the HC cohort, CD-GRS [mean] 0.0250 versus 0.0244 
respectively, p  =  8.0 x 10–8. Similarly, CD-associated genetic risk 
was significantly greater in the CD compared with the HC cohort, 
CD-GRS [mean] 0.0257 versus 0.0244 respectively, p = 1.1 x 10–91. 
CD-associated genetic risk was also significantly greater in the CD 
compared with the FDR cohort, CD-GRS [mean] 0.0257 versus 
0.0250 respectively, p = 2.0 x 10–9. In contrast IBD-associated genetic 
risk was similar comparing FDR and HC cohorts, IBD-GRS [mean] 
0.0231 versus 0.0231 respectively, p = 0.80. IBD-associated genetic 
risk was greater in the CD compared with the HC cohort, IBD-GRS 
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[mean] 0.0240 versus 0.0231 respectively, p = 1.1 x 10–280, and in the 
CD compared with the FDR cohort, IBD-GRS [mean] 0.0240 versus 
0.0231 respectively p = 7.1 x 10–82. [Table 1 and Figure 2].
3.3 Evaluation of differences in genetic risk scores 
between subgroups of FDRs
There was a modest but significant inverse correlation between CD 
proband age of diagnosis and the IBD-GRS of their corresponding 
FDR, correlation coefficient -0.08 [95% CI -0.14 - 0.01], p = 0.02 
[Figure 3]. An inverse correlation was also observed for the CD-GRS 
but this did not reach statistical significance: correlation coefficient 
-0.04 [95% CI -0.11 - 0.024], p = 0.21 [Supplementary Figure 3, 
available as Supplementary data at ECCO-JCC online]. There was a 
trend toward a modestly higher IBD-GRS in FDR less than 17 years 
old at study enrolment compared with those of 17 years or greater 
[p = 0.08]; however CD-GRS was similar between these subgroups 
of FDR. IBD-GRS and CD-GRS in the FDR cohort were similar 
comparing siblings and offspring [Supplementary Table 5, available 
as Supplementary data at ECCO-JCC online].
3.4. IBD and CD genetic risk categories in HC and 
FDR cohorts
There was a modest difference in the proportion of subjects assigned 
to each IBD genetic risk category comparing the FDR and HC 
cohorts [p = 0.04] with, for example, 8% versus 7% of each cohort 
respectively assigned to IBD genetic risk category 4.  There was a 
more marked difference in the proportion of subjects assigned to 
each CD genetic risk category comparing the FDR and HC cohorts 
[p = 5.1 x 10–15] with, for example, 21% versus 14% of each cohort 
respectively assigned to the CD genetic risk category 4 [Table 2].
4. Discussion
We genotyped healthy FDR of CD-affected individuals for 158 IBD 
risk loci, which is a comprehensive assessment of IBD genetic risk in 
FDR based on known IBD risk alleles. We demonstrate an enrich-
ment of IBD-associated risk alleles in FDR compared with HC as 
evidenced by the significant correlation in risk allele frequency differ-
ences between FDR and HC, and CD and HC, cohorts. Cumulative 
CD-specific genetic risk, expressed as a weighted genetic risk score, is 
increased in FDR compared with healthy controls, whereas cumula-
tive IBD genetic risk is similar between these groups.
We demonstrated that two CD-associated variants occurred more 
frequently in FDR than HC, rs2188962 in the region of the IBD5 
locus and rs3764147 in the region of LACC1, both of unknown 
function. One variant was enriched in the CD compared with the 
FDR cohort, rs6863411 [SPRY4, NDFIP1]. NDFIP1 is known to 
modulate T helper-17 cell differentiation,26 therefore it is possible 
that the increased representation of this variant in individuals with 
CD compared with FDR contributes to the dysregulated immune 
response observed in individuals with CD; however, this finding 
requires further validation.
In addition to evaluating allele frequencies of individual SNPs, 
we also performed a global assessment to determine whether the 
RAF of each of the 158 IBD-associated SNPs were similar in FDR 
and CD cohorts. This assessment showed that FDR are enriched 
with IBD risk alleles but not to the same degree as CD-affected 
Table 1. Comparison of CD-GRS and IBD-GRS between HC, FDR, 
and CD cohorts.
CD genetic risk score IBD genetic risk score
Mean SD Range Mean SD Range
HC 0.0244 0.003 0.013 – 0.040 0.0231 0.001 0.018 – 0.027
FDR 0.0250 0.003 0.014 – 0.035 0.0231 0.001 0.019 – 0.027
CD 0.0257 0.003 0.012 – 0.039 0.0240 0.001 0.020 – 0.029
SD, standard deviation; HC, healthy controls; FDR, first-degree relatives; 
CD, Crohn’s disease; GRS, genetic risk score.
CD-GRS pairwise comparisons: FDR versus HC cohort, p = 8.0 x 10–8; 
CD versus HC cohort, p = 1.1 x 10–91; CD versus FDR cohort, p = 2.0 x 10–9. 
IBD-GRS pairwise comparisons: FDR versus HC cohort, p = 0.8; CD versus 




































Figure 1. Correlation between the difference in risk allele frequency of 158 IBD-associated SNPs in FDR and HC versus CD and HC cohorts. For the 158 IBD-
associated SNPs evaluated, the differences in RAF between FDR and HC cohorts were strongly correlated with the differences in RAF between CD and HC 
cohorts; correlation coefficient 0.63 [95% confidence 0.53 - 0.72], p = 9.90 x 10–19. IBD, inflammatory bowel disease; HC, healthy controls; FDR, first-degree 
relatives; CD, Crohn’s disease; SNPs, single nucleotide polymorphisms; RAF, risk allele frequency.
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individuals; differences in RAF between FDR and HC, and CD & 
HC, cohorts were strongly correlated, generally in the same direc-
tion but of a lower magnitude. The finding has two possible expla-
nations; the first is that IBD genetic risk is genuinely elevated to a 
greater degree in CD-affected individuals compared with FDR. The 
other possibility is that a significant proportion of FDR with high 
IBD genetic risk develop overt disease at a younger age, resulting in 
an under-representation of FDR with this genetic profile, in cohorts 
such as ours, which recruited both paediatric and adult FDR. Some 
support for this second hypothesis was provided by the finding that 
there was a trend toward a modestly higher IBD-GRS in younger [< 
17 years] versus older [≥ 17 years] FDR. On balance we believe that 
both the aforementioned factors contribute to the higher IBD genetic 
risk observed in CD compared with the FDR.
As IBD is a complex polygenic disease, cumulative, subtle genetic 
effects may contribute more to overall disease susceptibility than the 
carriage of individual risk alleles. To reflect this cumulative genetic risk, 
IBD- and CD-weighted genetic risk scores [IBD-GRS and CD-GRS] 
were calculated utilising published ORs.23 There was a highly sig-
nificant increase in CD-GRS comparing HC and FDR cohorts. In 
contrast, IBD-GRS was similar comparing these cohorts. This find-
ing demonstrates that FDR of CD-affected individuals have increased 
cumulative CD-specific genetic susceptibility. Notably, the IBD-GRS 
and CD-GRS were significantly lower in the FDR compared with the 
CD cohort, which—as we discuss above—may reflect a true differ-
ence between the FDR and CD cohorts or a selection bias in the FDR 
cohort. Using the CD cohort as a ‘reference’ disease cohort, we also 
derived four incremental categories of IBD and CD genetic risk which 
were then used to assign individuals in the FDR and HC cohorts to 
one of four genetic risk categories. As expected, a significantly greater 
proportion of FDRs than HC were assigned to upper genetic risk cat-
egories [categories 3 & 4]. This segregation was much more marked 
for CD-GRS compared with IBD-GRS, reflecting the greater burden 
of CD-specific cumulative genetic risk compared with more general 
IBD genetic risk in the FDR cohort. Notably however, a proportion of 
HC were assigned to higher genetic risk categories with, for example, 
14% of healthy controls assigned to CD genetic risk category 4. This 
finding illustrates that higher IBD genetic risk occurs in the general 
population, contributing to the incidence of ‘sporadic’ IBD in indi-
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Figure 2. Distribution of IBD-GRS and CD-GRS in FDR, HC and CD cohorts; distributions of the CD-GRS and IBD-GRS in HC, FDR and CD cohorts. IBD, inflammatory 
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Figure 3. Scatterplot of FDR IBD-GRS and age of diagnosis of their corresponding CD proband. Each point [blue] represents a subject within the FDR cohort. 
The red line represents a line of best fit [r2 0.006]. There was a modest but significant inverse correlation between FDR IBD-GRS and the age of diagnosis of their 
corresponding CD proband; correlation coefficient -0.08 [95% confidence interval: -0.14 - -0.01], p = 0.02. IBD, inflammatory bowel disease; HC, healthy controls; 
FDR, first-degree relatives; CD, Crohn’s disease; GRS, genetic risk score.
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An important question for clinicians counselling relatives about 
the risk of developing IBD is whether their IBD genetic risk is related 
in any way to their own phenotypic characteristics or those of 
their IBD-affected family member. It has long been suggested that 
IBD genetic risk is enriched in individuals diagnosed with IBD at 
a younger age; however ,it is not known if this is also true of their 
first-degree relatives. A  recent report by Ananthakrishnan et  al., 
evaluating genetic risk in a CD cohort using Immunochip geno-
typing, demonstrating that earlier age of diagnosis was associated 
with a modest increase in IBD genetic risk burden in CD-affected 
individuals.27 Our data extend these findings by demonstrating that 
IBD genetic risk [IBD-GRS] is also modestly increased in healthy 
first-degree relatives whose CD-affected family member is diagnosed 
at a younger age. We did not find a similar correlation when specifi-
cally CD-associated genetic risk [CD-GRS] was examined. Finally, 
we examined whether any information on IBD genetic risk could be 
deduced from an individual’s relationship to their CD-affected fam-
ily member. We compared IBD and CD genetic risk between siblings 
and offspring of CD-affected individuals and found there to be no 
significant difference between these two groups of FDR.
Whereas epidemiological studies have long suggested increased 
IBD genetic risk in relatives of CD-affected individuals,3,4,5 we have 
demonstrated this conclusively. An obvious question posed by these 
data is whether genotyping provides any additional benefit over 
family history for assessment of IBD risk. There are a number of 
arguments which can be made against the utility of genotyping for 
IBD-associated SNPs in FDR. Family history, it can be argued, pro-
vides similar information to genotyping, and is less costly and easier 
to obtain. In addition, the problem of ‘missing heritability’ in IBD 
has resulted in concern regarding the practicality of using genetic 
risk factors in the context of disease susceptibility risk prediction.28 
We believe, however, that there are potential limitations to solely 
using family history as a risk prediction tool. Since significant genetic 
variance can occur within families,29 this poses substantial limits on 
the degree to which family history can be informative of disease risk. 
It has been demonstrated that the predictive power of family history 
for disease susceptibility diminishes quickly for lower-frequency dis-
eases such as CD, and SNP-based models have been shown not to 
have the same dependence on disease frequency.29 Our data demon-
strate that the cumulative IBD and CD genetic risk observed in FDR 
is variable. Therefore even in individuals with a family history of 
CD, a differential IBD-related genetic burden might be of importance 
in determining progression to overt disease. Determining whether 
IBD genetic risk characterisation might facilitate better risk stratifi-
cation of FDR requires a longitudinal study and therefore cannot be 
addressed in this report. However, such studies in FDR are required 
as the discovery of biomarkers, including genetic signatures, of 
disease susceptibility would be an important clinical advance, as the 
increasing understanding of environmental influences on IBD sus-
ceptibility are likely to result in novel preventive interventions which 
ameliorate IBD risk.
We acknowledge that this study has a number of limitations. The 
GEM project recruited FDR between the ages of 6 and 35  years, 
which limits the extrapolation of these data to the general popula-
tion of FDR of CD-affected individuals. The analysis was restricted 
to a solely Caucasian FDR cohort, but this was justified in order to 
minimise population stratification; and only the first recruited FDR 
from each family was used to avoid the non-independence of related 
subjects. The proportion of the FDR cohort of Jewish ancestry was 
known, but that of the CD and HC groups used for comparison was 
unknown, which was a limitation also. The GEM project did not 
co-recruit CD probands along with their healthy FDR and there-
fore direct comparisons between these groups could not be made. 
Nonetheless, these data presented represent the largest genotyping 
study of FDR of CD-affected individuals; our analyses are statisti-
cally powerful given the size of the cohorts included in the study; and 
finally, the use of the Immunochip allowed us to present comprehen-
sive genotyping of our cohorts for known IBD risk loci.
In conclusion, we have demonstrated that healthy FDR of 
CD-affected individuals are significantly enriched with IBD risk 
alleles compared with HC. In addition, cumulative CD-specific 
genetic risk is increased in FDR compared with a healthy cohort. 
This ‘at risk’ cohort will be a critical group for ongoing prospec-
tive follow-up to study the various microbial and environmental risk 
factors for CD, and will provide important insights into the inter-
relationship between genetic susceptibility and such triggers in dis-
ease pathogenesis.
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